Numen GTM brain

Numen is developing at-home urine biomarker testing and clinical decision support for healthcare teams, starting with bladder cancer pathways.

category

At-home cancer diagnostics and clinical decision support

market profile

  • text: Bladder cancer evaluation and recurrence monitoring can require repeated clinical appointments and invasive procedures.
  • text: Urine biomarker tests are an alternative or complement in bladder cancer evaluation, but intended uses and clinical evidence differ by product.

personas

  • title: Primary care physician
    pains:
    • Needs to decide which patients with blood in urine warrant further evaluation.
    • Referrals and multiple handoffs can interrupt a patient's path to diagnosis.
  • title: Urologist or clinical pathway lead
    pains:
    • Needs validated, actionable risk information integrated into existing care.
    • Recurring monitoring can impose repeated procedures and visits on patients.
  • title: Health system service line leader
    pains:
    • Patients may not complete recommended evaluation after initial symptoms.
    • Limited specialty capacity must be allocated to patients most likely to need it.

icp

  • text: US health systems and provider groups managing primary care and urology referrals, especially organizations seeking to improve follow-through.
  • text: Clinical partners evaluating home urine testing and EHR-integrated decision support for urologic pathways; commercial readiness is unconfirmed.

message pillars

  • text: Connect diagnostic testing with clinical guidance.
  • text: Make non-invasive testing accessible in the home.
  • text: Fit clinical decision support into existing workflows.
  • text: Pair results and outcomes to improve risk prediction over time.

objections

  • objection: Is the test clinically validated and cleared for the intended population?
    response: Request test-specific validation, intended use and regulatory status before clinical adoption; public status was not confirmed.
  • objection: How do results change an existing care pathway?
    response: Review ordering, EHR integration, physician interpretation and referral follow-up with the clinical team.
  • objection: How will this be paid for?
    response: Confirm reimbursement, contracting and patient cost directly; public pricing was not found.

competitors

  • name: Nucleix
    why: Offers urine-based testing for bladder cancer recurrence, a related clinical pathway.
  • name: Abbott Laboratories
    why: Its UroVysion bladder test is another diagnostic option in urology, with different use and workflow.

influencers

  • name: Thomas Carroll
    url: https://www.linkedin.com/in/thomas-carroll-62a60367
    why: Co-founder and cancer researcher discussing next-generation at-home diagnostics.
  • name: Luca Springer
    url: https://calmatters.digitaldemocracy.org/hearings/278735
    why: CEO publicly describes the diagnostic mission and research approach.

keywords

  • at home bladder cancer test
  • urine bladder cancer biomarker
  • hematuria risk assessment
  • bladder cancer recurrence monitoring
  • noninvasive urology diagnostics
  • clinical decision support hematuria

voice

  • mission driven
  • clinically oriented
  • accessible and concise

signals

  • text: A health system is redesigning its hematuria referral or follow-up pathway.
  • text: A urology group is assessing less invasive monitoring or home sample collection.

stack

  • EHR integration

hiring

  • Senior Signal Processing Engineer - Biosensor Readout

pricing

model: unknown

motion

sales_led

channels

  • clinical partnerships
  • LinkedIn

confidence

medium

Founders

  • name: Luca Springer
    title: Founder
    role: Founder
    bio: Luca is an expert in network science and computational game theory. He also has a strong policy background with a focus on healthcare systems. Luca previously worked at Stockdale Street, where he gathered years of experience analyzing, investing in, and helping grow healthcare, consumer, and technology companies. He holds an MSc in Computer Science and an MSc in Global Governance from the University of Oxford where he studied as a Rhodes Scholar. Luca is a Schmidt Futures ISF Fellow.
  • name: Thomas Carroll
    title: Founder
    role: Founder
    bio: Clinical cancer researcher with a specialty in bioinformatics, biomarkers, and methods development. Passionate about building better diagnostics and putting a dent in cancer mortality.

Back to YC companies